Skip to content

The Cardiac Uraemic fibrosis Detection in DiaLysis patiEnts study

The Cardiac Uraemic fibrosis Detection in DiaLysis patiEnts study: an observational cohort study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN99591655
Enrollment
35
Registered
2014-07-16
Start date
2015-06-01
Completion date
Unknown
Last updated
2018-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal failure Urological and Genital Diseases

Interventions

Each subject will have a heart tracing (ECG) performed before and after a haemodialysis session with some blood tests taken for research at the time of haemodialysis. The next day, subjects will under

Sponsors

NHS Greater Glasgow and Clyde (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Adult patients who have been treated with haemodialysis for <1 year are eligible

Exclusion criteria

Exclusion criteria: 1. Live donor transplant planned during the next 6 months 2. Predicted life expectancy <6months 3. Inability to give informed consent 4. Contraindications to MRI imaging (pacemaker, extreme claustrophobia) 5. Atrial fibrillation (makes gating of CMR images difficult)

Design outcomes

Primary

MeasureTime frame
Volume of myocardial fibrosis on cardiac MRI scanning. This will be measured by MRI scanning of the heart at baseline and on a follow up MRI 6 months later.

Secondary

MeasureTime frame
1. Change in serum brain natriuretic peptide 2. Simple correlations will be tested between presence/volume of fibrosis and serum markers of cardiac muscle enlargements/fibrosis and features of arrhythmia on ECG (heart tracing) Measured at baseline and 6 months later

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026